End-stage liver disease score and future liver remnant volume predict post-hepatectomy liver failure in hepatocellular carcinoma

Table 1 Patient characteristics in the two groups

Variable	PHLF (+) (n = 20)	PHLF (-) (n = 218)	P value
Age, years	57 (26-66)	51 (18-74)	0.077
Gender ratio, M/F	16/4	189/29	0.407
Platelet count, ×109/L	123 (28-240)	158 (30-535)	0.016
Prothrombin time, s	13.9 (10.8-16.4)	13.1 (9.9-17.1)	0.289
International normalized ratio	1.06 (1.00-1.26)	1.06 (0.88-1.44)	0.971
Total bilirubin, μmol/L	20.1 (6.2-43.1)	12.9 (3.9-37.1)	0.001
Albumin, g/L	37.3 (26.1-43.3)	38.8 (25.6-48.9)	0.029
Alanine aminotransferase, U/L	46.2 (16.9-94.7)	34.1 (8.5-302.6)	0.127
HBsAg positivity	90.0%	92.7%	0.667
Maximum tumor size, cm	6.5 (2.5-13.3)	5.5 (1.5-18.0)	0.270
sFLR	0.503 (0.378-0.780)	0.666 (0.361-0.995)	< 0.001
Major hepatectomy	40.0%	25.2%	0.152
MELD score	9 (6-12)	7 (6-12)	0.001

Date are presented as median (range) if not specified. PHLF: Post-hepatectomy liver failure; MELD: Model for end-stage liver disease; sFLR: Standardized future liver remnant.